<DOC>
	<DOC>NCT00927758</DOC>
	<brief_summary>To examine the post-dose changes in exhaled Nitric Oxide (eNO) following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines.</brief_summary>
	<brief_title>Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair</brief_title>
	<detailed_description />
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>must be able to speak, read, and understand English exhaled Nitrous Oxide levels must be greater than or equal to 60 ppb at screening and greater than or equal to 55 ppb at Visits 2, 9, and 16 must have history of at least 6 months of chronic, but stable asthma except for the presence of asthma, subjects must be in general good health past or present history of experiencing allergic reaction to medications used in this study subjects must not be receiving ongoing regular treatment with inhaled corticosteroids subjects must not have ragweed allergy subjects must have no recent history of respiratory infections for at least 1 month prior to screening and until the end of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>